Loading, please wait...
RESIDENT SEMINAR SCHEDULE
Wednesday, November 4, 2020
University of Health Sciences and Pharmacy - Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Allison Hotop, Pharm.D.
Inpatient Use of Sleep Medications and the Importance of Sleep Hygiene |
Taylor Schumacher, Pharm.D.
DOAC Usage in Hospitalized Patients with Renal Impairment, CKD, and ESRD |
Allison Wicker, Pharm.D.
Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement
|
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Karina Trac, Pharm.D.
Utilization of Intravenous Non-steroidal Anti-inflammatory Drugs |
Cameron Whitlock, Pharm.D.
Is There a Role of Direct Oral Anticoagulants in HIT? |
Rebecca Babalola, Pharm.D.
Is Low Level Viremia Predictive of Virologic Failure? |
Please join us for the fourth Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third and fourth floors, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, October 30, 2020 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close November 11, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Nov 4, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
The goal of this presentation is to give the audience a better understanding of medications used for sleep and sedation in the hospital. We will discuss the mechanisms of sleep and how that can be disrupted by an inpatient stay, the importance of sleep hygiene in the hospital, and the medications commonly used inpatient for sleep/sedation. We will also address common side effects of these agents, how we as pharmacists can intervene to help with sleep disruptions in the hospitals, and the outcomes associated with intervention. Those attending this presentation can expect to expand their knowledge of sleep and the pharmacist’s role to best improve sleep.
Objectives
- Identify the mechanism of action of common agents used for sleep/sedation
- Describe the difference between sleep and sedation
Speaker(s)/Author(s)
|
Allison Hotop, Pharm.D. |
Activity Number
0033-0000-20-064-L01-P
Date:
11/04/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 337 and Virtually
The utilization of DOACs in patients with renal impairment will be discussed with a specific focus on the inpatient setting. A brief review of pathophysiology and treatment strategies for anticoagulation will be covered in the presentation. The primary focus will be towards specific dosing regimens of DOACs in renal impairment in hospitalized patients. Current guidelines and primary literature addressing the safety and efficacy of DOACs in renal impairment will be discussed and compared to that of warfarin. Questions incorporating materials discussed during the presentation will be used as teaching materials interspersed throughout the seminar.
Speaker(s)/Author(s)
|
Taylor Schumacher, Pharm.D. |
Activity Number
0033-0000-20-061-L01-P
Date:
11/04/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 406 and Virtually
Transcatheter aortic valve replacement (TAVR) is an established treatment option in patients with severe aortic stenosis. Current practice guidelines provide weak recommendations regarding the potential antithrombotic options post-TAVR, and the risks of thromboembolic and bleeding complications associated with this procedure render the optimal antithrombotic regimen unclear. With the FDA indication for TAVR extended to low risk surgical patients in August 2019, selection of therapy has become even more critical. This program will address emerging evidence regarding the optimal antithrombotic regimens for patients both with and without indications for long-term anticoagulation.
Objectives
- List the current guideline recommendations regarding antithrombotic therapy after transcatheter aortic valve replacement.
- Summarize emerging data regarding antithrombotic strategies post transcatheter aortic valve replacement.
Speaker(s)/Author(s)
|
Allison Wicker, Pharm.D. |
Activity Number
0033-0000-20-059-L01-P
Date:
11/04/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
While the importance of adding intravenous nonsteroidal anti-inflammatory drugs (NSAIDs) to opioids has been widely acknowledged to decrease opioid consumption and opioid-related adverse effects, it remains unclear for the role of intravenous NSAIDs in multimodal pain management. There are currently four intravenous NSAIDs on the market, including the newly FDA approved intravenous meloxicam (ANJESO®) this year. The following presentation will describe the differences between the intravenous nonsteroidal anti-inflammatory drugs (NSAIDs) based on the pharmacology and pharmacokinetics, as well as the discussing the current evidence regarding the safety and efficacy of intravenous NSAIDs.
Speaker(s)/Author(s)
|
Karina Trac, Pharm.D. |
Activity Number
0033-0000-20-060-L01-P
Date:
11/04/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtually
Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening reaction to heparin that has about a 20% mortality rate. The core management goal of HIT is to stop the administration of heparin from all sources and initiate alternative agents in place. Current guidelines for the management of HIT recommend argatroban, bivalirudin and fondaparinux. The current recommended agents all require laboratory monitoring, parental administration, and a bridge to warfarin, which in turn increases labor and healthcare cost. Direct oral anticoagulants (DOACs) have recently emerged as a potential option in the management of HIT and may play a key role in overcoming the challenges of current therapies. The objective of this seminar is to summarize the current HIT guidelines, discuss limitations with current recommended treatment, and provide insight on the emerging data on DOACs.
Objectives
- Identify risk factors associated with heparin-induced thrombocytopenia (HIT)
- Compare and contrast the dosing of different DOACs in heparin-induced thrombocytopenia
- Summarize recent literature regarding the use of direct oral anticoagulants (DOACs) in HIT
Speaker(s)/Author(s)
|
Cameron Whitlock, Pharm.D. |
Activity Number
0033-0000-20-063-L01-P
Date:
11/04/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 406 and Virtually
This presentation will review current definitions and guidelines for low level viremia as well as potential causes. There will be a focus on low level viremia as a predictor of virologic failure as well as the impact of low level viremia on drug resistance, immune cells, and morbidity and mortality. The aim of the presentation is to outline proposed steps to take in patients with low level viremia.
Speaker(s)/Author(s)
|
Rebecca Babalola, Pharm.D. |
Activity Number
0033-0000-20-062-L01-P
Date:
11/04/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
